Bottom line
BIB vs SHPAX: the short answer
BIB (ProShares Ultra Nasdaq Biotechnology) and SHPAX (Health & Biotechnology Portfolio) are both etfs.
But BIB is far broader, holding 267 positions to 29 for SHPAX, so beyond the top names it adds exposure SHPAX doesn't have.
BIB is cheaper at 0.95% vs 3% — a difference of $205 a year per $10,000 invested.
Over five years, SHPAX returned +3.1% a year vs −1.0% for BIB (reporting dates differ).
SHPAX has a front-end sales load of up to 5.75%; the other does not.
Updated Nov 19, 2026
BIB vs SHPAX side by side
| BIB | SHPAX | |
|---|---|---|
| Type | ETF | Mutual fund |
| Fund family | ProShares | Saratoga Advantage |
| Category | Technology Sector | Technology Sector |
| Expense ratio | 0.95% | 3% |
| Annual cost per $10k | $95 | $300 |
| 10-yr cost on $10k (prospectus) | $1,401 | $3,702 |
| Max front load | None | 5.75% |
| 12b-1 fee | — | — |
| 1-yr return | +59.3% | −5.5% |
| 5-yr return (annualized) | −1.0% | +3.1% |
| 10-yr return (annualized) | +1.4% | +4.1% |
| Best quarter | +56.2% | +15.0% |
| Worst quarter | −42.7% | −13.0% |
| Net assets (fund) | $73.7M | $10.5M |
| Number of holdings | 267 | 29 |
| Portfolio turnover | 29% | 22% |
| Returns as of | Dec 31, 2025 | Dec 31, 2024 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | BIB | SHPAX | Difference |
|---|---|---|---|
| 2024 | −10.0% | +0.3% | −10.3% |
| 2023 | −1.3% | −0.4% | −0.9% |
| 2022 | −28.6% | +2.0% | −30.7% |
| 2021 | −5.9% | +16.7% | −22.6% |
| 2020 | +39.7% | +3.6% | +36.1% |
| 2019 | +45.5% | +16.2% | +29.3% |
| 2018 | −24.4% | −5.5% | −18.9% |
| 2017 | +40.8% | +12.0% | +28.8% |
| 2016 | −44.2% | −2.0% | −42.3% |
Source: Fund prospectus bar charts
Holdings overlap
6 of BIB's top 25 holdings also appear in SHPAX's top 25.
| Holding | BIB | SHPAX |
|---|---|---|
| Gilead Sciences, Inc. | 4.66% | 3.94% |
| Vertex Pharmaceuticals, Inc. | 4.65% | 3.36% |
| Amgen, Inc. | 4.48% | 5.04% |
| Regeneron Pharmaceuticals, Inc. | 3.21% | 3.93% |
| United Therapeutics Corp. | 1.22% | 6.17% |
| Incyte Corp. | 0.97% | 2.89% |
Source: SEC Form N-PORT
BIB top 10
- N/a — 7.35%
- ProShares GENIUS Money Market ETF — 6.80%
- Gilead Sciences, Inc. — 4.66%
- Vertex Pharmaceuticals, Inc. — 4.65%
- Amgen, Inc. — 4.48%
- N/a — 3.94%
- N/a — 3.26%
- Regeneron Pharmaceuticals, Inc. — 3.21%
- N/a — 2.62%
- Alnylam Pharmaceuticals, Inc. — 2.01%
SHPAX top 10
- Cardinal Health Inc — 6.44%
- Jazz Pharmaceuticals Plc — 6.19%
- United Therapeutics Corp — 6.17%
- Amgen Inc — 5.04%
- Mckesson Corp — 4.90%
- Lantheus Holdings Inc — 4.64%
- Exelixis Inc — 4.55%
- Novartis Ag — 4.50%
- Cencora Inc — 4.33%
- Gilead Sciences Inc — 3.94%
FAQ
What is the difference between BIB and SHPAX?
Which is cheaper, BIB or SHPAX?
Should I own both BIB and SHPAX?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.